The FDA has approved two medications for chronic weight management in adults with obesity or overweight. The first is Wegovy (semaglutide) injection, approved in 2021, and the second is Zepbound (tirzepatide) injection, approved in 2023. Both medications are indicated for use in adults with obesity or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol, in addition to a reduced-calorie diet and increased physical activity.
The effectiveness of these medications for chronic weight management was established in clinical trials, and they are part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity. Its important to note that these medications are prescription drugs and should be used under the guidance of a healthcare professional. Additionally, individuals should be cautious about over-the-counter weight loss products, as they may contain hidden drug ingredients and pose potential health risks.
